Log in

Relevant bibliographies by topics / Ovarios - Tumores / Books

To see the other types of publications on this topic, follow the link: Ovarios - Tumores.

Books on the topic 'Ovarios - Tumores'

Author: Grafiati

Published: 4 June 2021

Last updated: 2 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 books for your research on the topic 'Ovarios - Tumores.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Soslow, Robert A., and Carmen Tornos. Diagnostic pathology of ovarian tumors. Springer, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

H, Sobin L., and Serov S. F, eds. Histological typing of ovarian tumours. 2nd ed. Springer, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

1925-, Altchek Albert, and Cohen Carmel J, eds. Atlas of ovarian tumors. Igaku-Shoin, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Orr, Tamra. Ovarian tumors and cysts. Rosen Pub. Group, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Soslow, Robert A., and Carmen Tornos, eds. Diagnostic Pathology of Ovarian Tumors. Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-9751-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

James, Grant. Dermoid cyst of the ovary. s.n., 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Russell, Peter. Surgical pathology of the ovaries. 2nd ed. Churchill Livingstone, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Russell, Peter. Surgical pathology of the ovaries. Churchill Livingstone, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Scully, Robert E. Histological Typing of Ovarian Tumours. Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-58564-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Scully, Robert E. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Armed Forces Institute of Pathology, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

National Cancer Institute (U.S.), ed. Cancer of the ovary. U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

12

Zi gong ai fang zhi jiang zuo. Xie he wen hua you xian gong si, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

13

Weinstein, Ellen Michele. Inhibition of CA 125, a novel high molecular weight glycoprotein expressed by an ovarian carcinoma cell line: 0VCA 433, is related to glucocorticoid effects of altered cell growth, morphology, and growth pattern. s.n.], 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

14

Conway, Mary E. Ovarian cancer: January 1990 through January 1994, plus selected earlier references : 1908 citations. U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Library of Medicine, Reference Section, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

15

Jacobsen, G. Krag. Atlas of germ cells tumours. Munksgaard, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

16

Raoul Palmer Club of Gynaecological Endoscopy. European Congress. The management of adnexal cysts: Proceedings of the First European Congress of the Raoul Palmer Club of Gynaecological Endoscopy, Clermont-Ferrand, 10-11 September, 1992. Blackwell Scientific Publications, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

17

Sidiropoulos, Michael. Tumor-specific loss of human kallikrein 10 (KLK10/NES-1) by CpG Island hypermethylation in breast, ovarian and prostate cancers. National Library of Canada, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

18

Hayat, M. A. Methods of Cancer Diagnosis, Therapy, and Prognosis: Ovarian Cancer, Renal Cancer, Urogenitary tract Cancer, Urinary Bladder Cancer, Cervical Uterine Cancer, Skin Cancer, Leukemia, Multiple Myeloma and Sarcoma. Springer Science+Business Media B.V., 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

19

M, Roth Lawrence, and Czernobilsky Bernard, eds. Tumors and tumorlike conditions of the ovary. Churchill Livingstone, 1985.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

20

Soslow, Robert A., and Carmen Tornos. Diagnostic Pathology of Ovarian Tumors. Springer, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

21

Soslow, Robert A., and Carmen Tornos. Diagnostic Pathology of Ovarian Tumors. Springer, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

22

(Editor), Jonathan A. Ledermann, William J. Hoskins (Editor), Stanley B. Kaye (Editor), and Ignace B. Vergote (Editor), eds. Clinical Management of Ovarian Cancer. Informa Healthcare, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

23

Scully, Robert E., B. M. D. Clement Philip, and Robert H. Young. Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament: Atlas of Tumor Pathology (Afip Atlas of Tumor Pathology No. 23). American Registry of Pathology, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

24

Josephs, Debra H., Heather J. Bax, Giulia Pellizzari, James F. Spicer, Ana Montes, and Sophia N. Karagiannis. Antibody Therapeutics for Ovarian Carcinoma and Translation to the Clinic. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0001.

Full text

Abstract:

Despite improvements over the past decade in the treatment of ovarian cancer, many patients are at risk of recurrent disease and emerging drug resistance. The increased selectivity and reduced toxicity of molecularly targeted anti-cancer agents renders them attractive for development in ovarian cancer, and monoclonal antibodies targeting ovarian cancer-specific tumor antigens represent the largest such group investigated in this clinical setting. This chapter describes examples of monoclonal antibodies clinically evaluated for efficacy in ovarian cancer. These agents recognize molecular target

APA, Harvard, Vancouver, ISO, and other styles

25

Dermoid cyst of the ovary. s.n., 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

26

E, Bristow Robert, and Armstrong Deborah, eds. Ovarian cancer. Saunders/Elsevier, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

27

Reader, Jocelyn, Sarah Lynam, Amy Harper, Gautam Rao, Maya Matheny, and Dana M. Roque. Ovarian Tumor Microenvironment and Innate Immune Recognition. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0004.

Full text

Abstract:

Ovarian adenocarcinoma is typified by detection at late stages with dissemination of cancer cells into the peritoneal cavity and frequent acquisition of chemoresistance. A number of studies show the importance of the tumor microenvironment and innate immune recognition in tumor progression. Ovarian cancer cells can regulate the composition of their stroma to promote the formation of ascitic fluid rich in cytokines and bioactive lipids such as PGE2, and to stimulate the differentiation of stromal cells into a pro-tumoral phenotype. In response, cancer-associated fibroblasts, cancer-associated m

APA, Harvard, Vancouver, ISO, and other styles

28

Non-Epithelial Ovarian Tumors: Clinicopathological Issues. Nova Science Pub Inc, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

29

FRCPA, Russell Peter, and Farnsworth Annabelle, eds. Surgical pathology of the ovaries. 2nd ed. Churchill Livingstone, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

30

Histological Typing of Ovarian Tumours. Springer, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

31

Moerdler, Scott, and Xingxing Zang. PD-1/PDL-1 Inhibitors as Immunotherapy for Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0010.

Full text

Abstract:

Programmed death 1 (PD-1), a member of the B7-CD28 immunoglobulin superfamily, and its ligands PD-L1/PD-L2 inhibit T-cell activation. They also play a key role in the tumor microenvironment, allowing for cancer immune escape. PD-1 is induced on a variety of immune cells, including tumor-infiltrating lymphocytes (TILs), while PD-L1 is found on many types of solid tumors including ovarian cancer and some TILs. The use of immunocheckpoint inhibitors like anti-PD-1 and anti-PD-L1 therapies has been shown to reactivate the immune system to attack tumor cells. Ovarian cancers have been shown to be r

APA, Harvard, Vancouver, ISO, and other styles

32

Carton, James. Gynaecological pathology. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198759584.003.0012.

Full text

Abstract:

This chapter covers gynaecological pathology and includes vulval skin diseases, benign vulval tumours, vulval carcinoma, vaginal infections, vaginal tumours, cervical carcinoma, cervical screening, endometriosis, endometrial carcinoma, uterine leiomyomas (fibroids), uterine leiomyosarcoma, functional ovarian cysts, benign non-epithelial ovarian tumours, benign epithelial ovarian tumours, borderline epithelial ovarian tumours, ovarian carcinomas, pelvic inflammatory disease, ectopic pregnancy, polycystic ovarian syndrome, hydatidiform mole, and pre-eclampsia.

APA, Harvard, Vancouver, ISO, and other styles

33

Carton, James. Gynaecological pathology. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199591633.003.0011.

Full text

Abstract:

Vulval skin diseases 186Benign vulval tumours 187Vulval carcinoma 188Vaginal infections 190Vaginal tumours 191Cervical carcinoma 192Cervical screening 194Endometriosis 195Endometrial carcinoma 196Uterine leiomyomas 198Functional ovarian cysts 200Polycystic ovarian syndrome 202Benign ovarian tumours 204Ovarian carcinomas ...

APA, Harvard, Vancouver, ISO, and other styles

34

Chapman, Hannah, and Christine Elwell. Ovarian and testicular cancer. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0328.

Full text

Abstract:

Ovarian cancer is the fifth most common cancer in females in the UK. In contrast, testicular cancer is a rare disease: there were 2138 new cases of testicular cancer diagnosed in 2008 in the UK, and only 70 deaths. Ninety per cent of all ovarian cancers are of epithelial origin, although germ cell and sex cord–stromal cell tumours also occur. In contrast, 95% of testicular cancers are germ cell tumours, with stromal cell tumours and lymphomas making up the remaining 5%. This chapter discusses ovarian cancer and testicular cancer, including definitions of the diseases and their etiologies, typi

APA, Harvard, Vancouver, ISO, and other styles

35

Webb, Penelope M., Susan J. Jordan, and David J. Hunter. Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/oso/9780190676827.003.0019.

Full text

Abstract:

Apart from oral contraceptive use and, possibly, breastfeeding, there are few readily modifiable risk factors for ovarian cancer. There is little evidence for a role of diet while smoking appears to increase risk of mucinous ovarian tumors only. It is likely that obesity has a modest effect on risk, although this may be limited to the nonserous subtypes and/or women who do not use menopausal hormones, while the possible risk-reduction associated with use of aspirin has yet to be confirmed in prospective studies. It is unclear whether physical activity influences ovarian cancer risk. Together w

APA, Harvard, Vancouver, ISO, and other styles

36

Lavoué, Vincent, Patrick Legembre, Jean Levêque, Fabrice Foucher, Sébastien Henno, and Florian Cabillic. Ovarian Cancer Immunity. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0003.

Full text

Abstract:

Epithelial ovarian cancer (EOC) is a significant cause of cancer-related mortality in women, and there has been no substantial decrease in the death rates due to EOC in the past three decades. Thus, basic knowledge regarding ovarian tumor cell biology is urgently needed to allow the development of innovative treatments for EOC. Traditionally, EOC has not been considered an immunogenic tumor, but there is evidence of an immune response to EOC in patients. Clinical data demonstrate that an anti-tumor immune response and immune evasion mechanisms are correlated with a better and lower survival, r

APA, Harvard, Vancouver, ISO, and other styles

37

National Institutes of Health (U.S.), ed. What you need to know about ovarian cancer. 2nd ed. National Institutes of Health, National Cancer Institute, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

38

WHO Classification of Tumours of the Female Reproductive Organs. World Health Organization, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

39

N, Chatzigeorgiou Konstantinos, and Bontis John N, eds. Peritoneal carcinomatosis from ovarian cancer. Nova Science Publishers, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

40

Ovarian Cancer: Methods and Protocols (Methods in Molecular Medicine). Humana Press, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

41

Harnden, Patricia. Germ Cell Tumours V. Edited by Patricia Harnden. Springer-Verlag New York, Inc., 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

42

Farghaly, Samir A. Adoptive Cell Immunotherapy for Epithelial Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0005.

Full text

Abstract:

The standard management for epithelial ovarian cancer (EOC) is a combination of aggressive debulking surgery with residual tumor of less than 1 cm and platinum-based chemotherapy. However, a high percentage of patients experience disease recurrence. Extensive efforts to find new therapeutic options have been made, albeit cancer cells develop drug resistance and malignant progression occurs. Novel therapeutic strategies are needed to enhance progression-free survival and overall survival of patients with advanced EOC. Several preclinical and clinical studies investigated feasibility and efficac

APA, Harvard, Vancouver, ISO, and other styles

43

Jacobsen, Grete Kraq, and A. Talerman. Atlas of Germ Cell Tumours. Wiley-Blackwell, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

44

Alharbi, Yousef, Manish S. Patankar, and Rebecca J. Whelan. Antibody-Based Therapy for Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0006.

Full text

Abstract:

With their role in connecting disease-associated antigens to the cellular immune response, antibodies hold considerable promise as therapeutic agents. This chapter discusses three classes of therapeutic antibodies that have been developed for use in ovarian cancer therapy. The first includes antibodies selected against tumor-associated antigens such as MUC16/CA125, mesothelin, epithelial cell adhesion molecule, and folate receptor α‎. Antibodies in the second class target proteins such as CTLA-4 and PD1 that act as immune response checkpoint receptors. The third class of antibodies target secr

APA, Harvard, Vancouver, ISO, and other styles

45

The Tumor Microenvironment of High Grade Serous Ovarian Cancer. MDPI, 2019. http://dx.doi.org/10.3390/books978-3-03897-555-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Publications, ICON Health. Ovarian Tumors - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References. ICON Health Publications, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

47

(Editor), M. A. Bruhat, and Raoul Palmer Club of Gynaecological Endoscopy European Congress 1992 (Corporate Author), eds. The Management of Adnexal Cysts: Proceedings of the First European Congress of the Raoul Palmer Club of Gynecologic Endoscopy, Clermont-Ferrand, 10-. Blackwell Science Inc, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

48

Drerup, Justin M., Curtis A. Clark, and Tyler J. Curiel. Clinical Trials of Ovarian Cancer Immunotherapy and Future Directions. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0013.

Full text

Abstract:

Ovarian cancer (OC) is an immunogenic tumor and among the first where measures of anti-tumor immunity correlated with improved survival. Thus, immunotherapy could be a viable OC treatment modality. Nonetheless, clinical OC immunotherapy trials have demonstrated only modest successes at best, and there is currently no Food and Drug Administration (FDA)approved OC immune therapy despite recent successes in other carcinomas and lymphomas and FDA-approved immunotherapy agents for them. New data suggest specific impediments to effective de novo and treatment-induced anti-OC immunity and support the

APA, Harvard, Vancouver, ISO, and other styles

49

S, Bartlett John M., ed. Ovarian cancer: Methods and protocols. Humana Press, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

50

Hodgkiss, Andrew. Psychiatric consequences of particular cancers. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198759911.003.0004.

Full text

Abstract:

Certain tumour types can cause psychopathology through direct biological mechanisms such as metastatic spread to the brain, release of onconeuronal antibodies, ectopic hormone secretion, or release of pro-inflammatory cytokines. Lung cancers, adenocarcinoma of the pancreas, brain tumours, and ovarian tumours are considered in detail. Confusional states due to brain metastases, syndrome of inappropriate ADH secretion, hypercalcaemia of malignancy, and anti-Hu encephalitis are found in lung cancers. Severe depression, due to interleukin-6 release and its actions on the HPA axis and tryptophan me

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!